JP2022513099A5 - - Google Patents

Info

Publication number
JP2022513099A5
JP2022513099A5 JP2021527926A JP2021527926A JP2022513099A5 JP 2022513099 A5 JP2022513099 A5 JP 2022513099A5 JP 2021527926 A JP2021527926 A JP 2021527926A JP 2021527926 A JP2021527926 A JP 2021527926A JP 2022513099 A5 JP2022513099 A5 JP 2022513099A5
Authority
JP
Japan
Prior art keywords
composition according
tnf
vector
cells
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021527926A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513099A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/062009 external-priority patent/WO2020106619A1/en
Publication of JP2022513099A publication Critical patent/JP2022513099A/ja
Publication of JP2022513099A5 publication Critical patent/JP2022513099A5/ja
Pending legal-status Critical Current

Links

JP2021527926A 2018-11-19 2019-11-18 自殺遺伝子 Pending JP2022513099A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862769405P 2018-11-19 2018-11-19
US62/769,405 2018-11-19
US201862773372P 2018-11-30 2018-11-30
US62/773,372 2018-11-30
US201962791464P 2019-01-11 2019-01-11
US62/791,464 2019-01-11
PCT/US2019/062009 WO2020106619A1 (en) 2018-11-19 2019-11-18 Suicide gene

Publications (2)

Publication Number Publication Date
JP2022513099A JP2022513099A (ja) 2022-02-07
JP2022513099A5 true JP2022513099A5 (enExample) 2022-11-21

Family

ID=68848450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021527926A Pending JP2022513099A (ja) 2018-11-19 2019-11-18 自殺遺伝子

Country Status (18)

Country Link
US (1) US20220023343A1 (enExample)
EP (1) EP3883959A1 (enExample)
JP (1) JP2022513099A (enExample)
KR (1) KR20210093977A (enExample)
CN (1) CN113272320A (enExample)
AU (1) AU2019384115A1 (enExample)
BR (1) BR112021009634A2 (enExample)
CA (1) CA3120349A1 (enExample)
CL (1) CL2021001300A1 (enExample)
CO (1) CO2021007824A2 (enExample)
EC (1) ECSP21044662A (enExample)
IL (1) IL283242A (enExample)
MX (1) MX2021005847A (enExample)
PE (1) PE20211236A1 (enExample)
PH (1) PH12021551142A1 (enExample)
SG (1) SG11202105238YA (enExample)
TW (1) TW202039538A (enExample)
WO (1) WO2020106619A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311837A (en) 2021-10-20 2024-05-01 Takeda Pharmaceuticals Co Compositions targeting bcma and methods of use thereof
EP4493581A1 (en) * 2022-03-18 2025-01-22 University of Rochester Combination therapy for treatment of cancer, methods and systems of delivery thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3817955A1 (de) 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
US6143866A (en) 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
WO1994000555A2 (en) * 1992-06-25 1994-01-06 Cetus Oncology Corporation Compositions for the inhibition of protein hormone formation and uses thereof
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
JPWO2005035586A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JP5956982B2 (ja) * 2010-05-27 2016-07-27 メルク・シャープ・エンド・ドーム・コーポレイション 改善された特性を有する抗体の製造方法
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
EP4166148B1 (en) * 2014-06-06 2026-02-18 Memorial Sloan-Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
EA035898B1 (ru) * 2014-10-03 2020-08-28 НАНОТИКС, ЭлЭлСи Композиции и способы для ингибирования биологической активности растворимых биомолекул
AU2016306209B2 (en) * 2015-08-07 2023-07-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific CAR T-cells for solid tumor targeting
KR20240024328A (ko) * 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
CN107365798B (zh) * 2017-07-13 2020-07-14 山东省齐鲁细胞治疗工程技术有限公司 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用
CN107245106B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd10的嵌合抗原受体及其应用
CN107337737B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种嵌合抗原受体及其应用
CN107245107B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd20的嵌合抗原受体及其应用
CN107312098B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd22的嵌合抗原受体及其应用
CN107312097B (zh) * 2017-07-18 2020-06-16 深圳市免疫基因治疗研究院 一种基于cd30的嵌合抗原受体及其应用
CN107400168B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用

Similar Documents

Publication Publication Date Title
US11802143B2 (en) Therapeutic agents
CN113260368B (zh) 抗gpc3嵌合抗原受体(car)与反式共刺激分子的组合及其治疗用途
JP7198670B2 (ja) 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用
Redeker et al. Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination
CN106536563B (zh) 嵌合抗原受体
CN103483452B (zh) 双信号独立的嵌合抗原受体及其用途
US12577287B2 (en) T cell receptors and methods of use thereof
JP2016519068A5 (enExample)
JP2018501786A5 (enExample)
JP2016521709A5 (enExample)
KR20190039397A (ko) 인간 백혈구 항원 제한된 감마 델타 t 세포 수용체 및 이의 사용 방법
KR20180057723A (ko) 항-cd30 키메라성 항원 수용체
JP2021525534A5 (enExample)
JP7825752B2 (ja) Ｔ細胞受容体及びその使用方法
CN112055717A (zh) 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
JP2019512251A (ja) Ｐｄ−１及び４−１ｂｂの融合タンパク質
CN112533629A (zh) 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
KR20210149048A (ko) T 세포 수용체 및 이의 사용 방법
JP2024504048A (ja) 発現が増加した変異細胞内ドメインを含むキメラ共刺激タンパク質
JP7727547B2 (ja) Ｔ細胞受容体及びその使用方法
AU2018378955A1 (en) Methods for enhancing and maintaining CAR-T cell efficacy
JP2022513099A5 (enExample)
KR20220087431A (ko) T 세포 수용체 및 이의 사용 방법
TWI881993B (zh) Ｔ細胞受體及其使用方法
TWI869426B (zh) Ｔ細胞受體及其使用方法